Theralase Technologies Inc. V.TLT

did not like

[jicoop]

Did not like the 47.8% no response number, very high. :(

[bartlman]

Yep. Would've been nice to have some questions asked about it. Is this the same group where bladder measurements were too small and these guys did not get the optimal treatment?

[enriquesuave]

That was the 8 from the initial 12 undertreated patients and probably patient number 4 from PH1 who also didn't receive an Optimized treatment. We will need to see the data on optimized treated patients once available. Another 3 at next Quarterly report  imo

[enriquesuave]

We already knew about those 9 patients.  I believe only 2 or 3 patients from the first set of 12 PH2 patients got a 2nd treatment which was optimized, plus now patients 13 and on got 1st optimized treatment.   Will they post a replay of AGM  I came in a bit late.    

[StevenBirch]

Only 12.5% no response for those who received the optimized treatment though. I would say let's wait for the quarterly update and any new data that we get. Pretty bland presentation actually.

[enriquesuave]

That 12.5 no response in the optimized group was patient who suffered both the grade 3 and 5 SAE and died IMHO. This patient had a negative or no cancer at 30 day cytology analysis, but sadly  died of heart failure before 3 months Cystoscope exam.  

[VentureGuy24]

Anyone notice......no doctors this year! Why no Jewett? Why no Lilge? ETC

[enriquesuave]

I guess there wasn't enough data to get the Drs to speak. Next quarterly in a month should be more informative IMO. Just hope data of optimized patients continues to be good. 

[DJDawg]

So if I'm hearing everyone correctly no new patient data? No new info that would alter this thread's previous discussion about the existing patients? I can live with that (till next newsletter) but wanted to be sure. Any comment on that one patient who passed away? Were they removed from data altogether or are they that non-responder from the most recent newsletter?

[Tapps21]

There were many issues not addressed and It appeared long term  data was not available to provide concrete guidance moving forward. The "mess up" at the beginning of P2 is evident that it has played a part in this. P2 paitents with the optimized treatment will be telling as to what the company really has to offer the "Cancer" world. Fingers crossed Money and funding was